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Abstract: Residual renal function (RRF) is associated with left
ventricular (LV) hypertrophy as well as all-cause and cardiovascular
(CV) mortality in patients with end-stage renal disease. However, no
studies have yet examined the serial changes in echocardiographic
findings according to the rate of RRF decline in incident dialysis
patients.
A total of 81 patients who started peritoneal dialysis (PD) between
2005 and 2012 at Yonsei University Health System, Seoul, South Korea,
and who underwent baseline and follow-up echocardiography within the
first year of PD were recruited. Patients were dichotomized into
‘‘faster’’ and ‘‘slower’’ RRF decline groups according to the median
values of RRF decline slope (1.60mL/min/y/1.73m2).
Baseline RRF and echocardiographic parameters were comparable
between the 2 groups. During the first year of PD, there were no
significant changes in LV end-diastolic volume index (LVEDVI), left
atrial volume index (LAVI), or LV mass index (LVMI) in the ‘‘faster’’
RRT decline group, while these indices decreased in the ‘‘slower’’ RRT
decline group. The rate of RRF decline was a significant determinant of
1-year changes in LVEDVI, LAVI, and LVMI. The linear mixed model
further confirmed that there were significant differences in the changes
in LVEDVI, LAVI, and LVMI between the 2 groups (P¼ 0.047, 0.048,
and 0.001, respectively). During a mean follow-up duration of 31.9
months, 4 (4.9%) patients died. Compared with the ‘‘slower’’ RRF
decline group, CV composite (20.29/100 vs 7.18/100 patient-yearsMD, PhD, Tae-Hyu hD,
ang, MD, PhD
decline rate. On multivariate Cox regression analysis, patients with
‘‘faster’’ RRF decline rate showed 4.82-, 4.44-, and 7.37-fold higher
risks, respectively, for each clinical outcome.
Preservation of RRF is important for conserving cardiac perform-
ance, resulting in an improvement in clinical outcomes of incident PD
patients.
(Medicine 94(7):e427)
Abbreviations: BSA = body surface area, CAD = coronary artery
disease, CHF = congestive heart failure, CV = cardiovascular, DM
= diabetes mellitus, ESRD = end-stage renal disease, HbA1c =
hemoglobin A1c, HD = hemodialysis, hs-CRP = high-sensitivity C-
reactive protein, iPTH = intact parathyroid hormone, IRB =
Institutional Review Board, LAE = left atrial enlargement, LAV =
left atrial volume, LAVI = left atrial volume index, LMM = linear
mixed model, In hs-CRP = natural log values of high-sensitivity C-
reactive protein, LV = left ventricle, LVEDVI = left ventricular
end-diastolic volume index, LVESVI = left ventricular end-systolic
volume index, LVH = left ventricular hypertrophy, LVMI = left
ventricular mass index, PAD = peripheral arterial disease, PD =
peritoneal dialysis, PP = pulse pressure, RRF = residual renal
function.
INTRODUCTION
C ardiovascular (CV) disease is prevalent and is the mostcommon cause of morbidity and mortality in patients with
end-stage renal disease (ESRD). Even though coronary artery
disease (CAD) and arrhythmia are not uncommon, left ventri-
cular (LV) hypertrophy (LVH) is the most frequent CV mani-
festation in these patients.1 LVH is known to be present in more
than 70% of incident ESRD patients and to be a significant
independent predictor of CV mortality not only in patients with
hypertension but also in those with ESRD.2–5 Recently, several
studies have demonstrated that left atrial volume (LAV) index
(LAVI) is also an independent predictor of mortality in patients
with ESRD.6–8
The importance of residual renal function (RRF) has been
highlighted in patients with ESRD. The loss of RRF is closely
linked to fluid overload, sodium retention, hypertension, LVH,
malnutrition, inflammation, endothelial dysfunction, and ane-
mia, all of which contribute to a higher prevalence of CV
disease in dialysis patients.9,10 In addition, lower RRF was
associated with increased morbidity and mortality in ESRD
patients receiving hemodialysis (HD) or peritoneal dialysisn PD patients, RRF and fluid removal,
were shown to be independent predictors
n though a number of previous studies
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found that RRF was a favorable factor for clinical outcomes in
dialysis patients, most of these studies used only baseline RRF
and clarified its impact on all-cause and/or CV mortality.
RRF decreases progressively after the initiation of dialysis,
and thus it has been surmised that the impact of the rate of RRF
decline rather than baseline RRF is a more important determinant
of clinical outcomes of ESRDpatients on dialysis. Supporting this
point of view, a study by Liao et al18 revealed that patients with
faster RRF decline after PD initiation had worse clinical out-
comes, and that the rate of RRF decline rather than baseline RRF
was an independent risk factor for technique failure in incident PD
patients. The authors also found that the rate of RRF decline was
superior to baseline RRF in predicting patient and technique
survival in these patients. However, they did not elucidate the
mechanism of poor clinical outcomes in patients with a rapid
decline of RRF. Since there is a close relationship between RRF
and cardiac dysfunction inESRDpatients, the rate ofRRF decline
may have an effect on the changes in cardiac function, which is
closely associated with patient morbidity and mortality. The
specifics of this hypothesis have never been explored.
In this study, therefore, we aimed to clarify the changes in
echocardiographic findings during the first year of dialysis
therapy according to the rate of RRF decline in incident PD
patients. Furthermore, we elucidated the prognostic impact of
the RRF decline rate on clinical outcome.
PATIENTS AND METHODS
Patients
Initial recruitment for this retrospective cohort study
included 148 patients who started PD between January 1,
2005 and July 31, 2012 at Yonsei University Health System,
Seoul, South Korea, and who underwent echocardiography, urea
kinetic study, and peritoneal equilibration test within 1 month of
PD initiation. Among these patients, we excluded those who
were younger than 18 years, were anuric (<100mL/d) at the
time of PD initiation, had a history of HD or kidney transplan-
tation prior to PD, had an underlying active malignancy or acute
infection, or died within 3 months of PD initiation. Patients who
did not receive follow-up echocardiography within the first year
of PD treatment were also excluded. Thus, a total of 81 incident
PD patients were included in the final analysis.
This study was carried out in accordance with the Declara-
tion of Helsinki and approved by the Institutional Review Board
(IRB) of Yonsei University Health System Clinical Trial Center.
Since this was a retrospective, medical record–based study and
the study subjects were unidentified, the IRB waived the need
for written consent from the patients.
Data Collection
Demographic and clinical data, including age, gender,
body mass index (calculated as weight/height2), primary renal
disease, comorbidities, and medications, were recorded at the
time of PD initiation. CAD was defined as a history of angio-
plasty, coronary artery bypass grafts, myocardial infarction, or
angina, while peripheral arterial disease (PAD) was defined as a
history of claudication, ischemic limb loss and/or ulceration, or
peripheral revascularization procedure.
Laboratory dataweremeasured from fasting blood samples,
whichweredrawnat2hours after the first PDexchangewith1.5%
Koo et aldextrose dialysate on the daywhen the first urea kinetic studywas
performed. The following variables were included: hemoglobin,
blood urea nitrogen, creatinine, calcium, phosphorus, alkaline
2 | www.md-journal.comphosphatase, intact parathyroid hormone (iPTH), glucose, hemo-
globin A1c (HbA1c), albumin, lipid profile, sodium, potassium,
bicarbonate, iron profile, N-terminal pro–B-type natriuretic pep-
tide, cardiac troponin T, and high-sensitivity C-reactive protein
(hs-CRP). Estimated glomerular filtration rate was calculated
using the 4-variable Modification of Diet in Renal Disease study
equation.19 A peritoneal equilibrium test was conducted to
determine peritoneal transport characteristics, and dialysis ade-
quacy and RRF were measured within 1 month of beginning PD
and every 6months thereafter. Peritoneal transport characteristics
were assessed using equilibration ratios between dialysate and
plasma creatinine, which were determined by a standardized
peritoneal equilibration test using 2L 4.25% dextrose dwell with
dialysate samples taken at 0, 2, and4hours anda plasmasampleat
2 hours. According to their 4-hour dialysate-to-plasma creatinine
ratios, patientswere categorized in 1 of the following 4 peritoneal
transport groups: high, high average, low average, or low.20
Drained whole dialysate and 24-hour urinewere collected within
1 day before the peritoneal equilibration test. Creatinine and urea
nitrogenweremeasured in blood, urine, and drained dialysate. To
assess dialysis adequacy, weekly Kt/Vurea was calculated as the
ratio of 24-hour urinary and drained dialysate urea clearance to
total body water.21 RRF was calculated as an average of the 24-
hour urine urea and creatinine clearance and was adjusted for
body surface area (BSA).22 Lean body mass was estimated by
creatinine kinetics and was divided by dry weight to produce a
percent lean body mass.23
Echocardiographic Measurements
Echocardiography was performed in the morning with an
empty abdomen, based on the imaging protocol recommended
by the American Society of Echocardiography using a SONOS
7500 (Philips Ultrasound, Bothell, WA). LV systolic function
was estimated by LVejection fraction using a modified biplane
Simpson method from the apical 2-chamber and 4-chamber
views. LV mass was determined using the method described
by Devereux et al,24 and the LV mass index (LVMI) was
calculated by dividing LV mass by BSA. LVH was defined as
LVMI> 131 g/m2 for men and>100 g/m2 for women.25 Hyper-
trophy was considered concentric if LV relative wall thickness
was>0.43, and patientswith normal LVmasswere considered to
have normal LV geometry if relativewall thickness was0.43 or
to have concentric remodeling if relative wall thickness was
increased.26 LAV was assessed using the biplane area–length
method from the apical 2- and 4-chamber views andwas indexed
for BSA. Mitral inflow was assessed with Doppler echocardio-
graphy from the apical 4-chamber view (E, A). Pulsed wave
tissue Doppler imaging of the septal mitral annulus was also
obtained from the apical 4-chamber view (E0, A0). Right ven-
tricular systolic pressure was calculated using the modified
Bernoulli equation (4 [tricuspid systolic jet]2þ 10mm Hg).
Outcome Measures
The aim of this study was to clarify time-dependent 1-year
changes in echocardiographic parameters according to the rate
of RRF decline. Independent factors associated with the RRF
decline rate and the impact of RRF decline rate on clinical
outcomes, such as all-cause mortality, composite of death or
hospitalization, CV composite, infection composite, new-onset
CV diseases, technique failure, and PD peritonitis, were also
Medicine  Volume 94, Number 7, February 2015elucidated. A CV event was defined as death or hospitalization
from CAD, congestive heart failure (CHF), arrhythmia, pul-
monary edema, cerebrovascular disease, or PAD.
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Statistical Analysis
Statistical analysis was performed using SPSS for Win-
dows, version 18.0 (SPSS Inc, Chicago, IL). Continuous vari-
ables were expressed as mean standard deviation or median
Medicine  Volume 94, Number 7, February 2015(interquartile range), while categorical variables were expressed
as number (percentage). Normality of distribution was ascer-
tained by the Shapiro–Wilk test. To determine the rate of RRF
TABLE 1. Baseline Demographic and Clinical Characteristics of S
Variables
Total
(N¼ 81)
Age, y 51.5 11.7
Sex (male) 40 (49.4%)
BMI, kg/m2 23.2 3.5
Systolic BP, mm Hg 133.5 21.6
Diastolic BP, mm Hg 77.3 12.4
Pulse pressure, mm Hg 56.2 16.9
Primary cause of end-stage renal disease
Diabetes 31 (38.3%)
Hypertension 12 (14.8%)
Glomerulonephritis 20 (24.7%)
Interstitial nephritis 3 (3.7%)
Congenital/hereditary disease 3 (3.7%)
Others 6 (7.4%)
Unknown 6 (7.4%)
Comorbid disease
Hypertension 73 (90.1%)
Diabetes 37 (45.7%)
Chronic lung disease 12 (14.8%)
CAD 19 (23.5%)
PAD 3 (3.7%)
Congestive heart failure 17 (21.0%)
Arrhythmia 7 (8.6%)
Cerebrovascular disease 17 (21.0%)
Connective tissue disease 11 (13.6%)
Liver disease 1 (1.2%)
Malignancy 1 (1.2%)
All CVD

32 (39.5%)
Heart diseasey 27 (33.3%)
Modified CCI 5.49 2.47
Medications
RAS blockers 72 (88.9%)
Diuretics 49 (60.5%)
b blockers 49 (60.5%)
CCB 62 (76.5%)
Nitrate 9 (11.1%)
Other BP medications 9 (11.1%)
Statin 25 (30.9%)
Aspirin 19 (23.5%)
Plavix 9 (11.1%)
Vitamin D 25 (30.9%)
Ca-based P binder 58 (71.6%)
Non-Ca-based P binder 7 (8.6%)
ESA 64 (79.0%)
Iron agents 66 (81.5%)
BMI¼ body mass index, BP¼ blood pressure, Ca¼ calcium, CAD¼ cor
comorbidity index, CVD¼ cardiovascular disease, ESA¼ erythropoiesis-
RAS¼ renin–angiotensin system, RRF¼ residual renal function.
Composite of CAD, PAD, congestive heart failure, arrhythmia, and ce
yComposite of CAD, congestive heart failure, and arrhythmia.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.decline during the first year of PD, linear regression analysis of
serial RRF was performed for each patient; the slope was
expressed as the regression coefficient. Patients were dichot-
omized into ‘‘faster’’ and ‘‘slower’’ RRF decline groups based
RRF Decline Rate and Changes in Echocardiographyon the median values of RRF decline slope. Patient demo-
graphics, clinical characteristics, laboratory findings, and echo-
cardiographic parameters were compared between the 2 groups
tudy Patients
Faster RRF Decline
Group (N¼ 41)
Slower RRF Decline
Group (N¼ 40) P
51.0 12.4 52.1 11.2 0.702
23 (56.1%) 17 (42.5%) 0.221
23.0 2.8 23.4 4.1 0.670
139.7 19.7 127.1 21.9 0.021
77.5 12.4 77.1 12.6 0.905
62.2 17.3 50.0 14.1 0.004
0.095
20 (48.8%) 11 (27.5%)
5 (12.2%) 7 (17.5%)
9 (22.0%) 11 (27.5%)
2 (4.9%) 1 (2.5%)
2 (4.9%) 1 (2.5%)
3 (7.3%) 3 (7.5%)
0 (0.0%) 6 (15.0%)
38 (92.7%) 35 (87.5%) 0.482
23 (56.1%) 14 (35.0%) 0.057
7 (17.1%) 5 (12.5%) 0.562
11 (26.8%) 8 (20.0%) 0.468
2 (4.9%) 1 (2.5%) 0.999
9 (22.0%) 8 (20.0%) 0.829
3 (7.3%) 4 (10.0%) 0.712
11 (26.8%) 6 (15.0%) 0.191
4 (9.8%) 7 (17.5%) 0.309
0 (0.0%) 1 (2.5%) 0.494
0 (0.0%) 1 (2.5%) 0.494
17 (41.5%) 15 (37.5%) 0.715
17 (41.5%) 10 (25.0%) 0.116
5.77 2.84 5.20 2.04 0.367
36 (87.8%) 36 (90.0%) 0.999
30 (73.2%) 19 (47.5%) 0.018
23 (56.1%) 26 (65.0%) 0.413
32 (78.0%) 30 (75.0%) 0.746
5 (12.2%) 4 (10.0%) 0.999
6 (14.6%) 3 (7.5%) 0.482
11 (26.8%) 14 (35.0%) 0.426
10 (24.4%) 9 (22.5%) 0.841
6 (14.6%) 3 (7.5%) 0.482
12 (29.3%) 13 (32.5%) 0.753
27 (65.9%) 31 (77.5%) 0.245
2 (4.9%) 5 (12.5%) 0.264
35 (85.4%) 29 (72.5%) 0.155
33 (80.5%) 33 (82.5%) 0.816
onary artery disease, CCB¼ calcium channel blocker, CCI¼Charlson
stimulating agent, P¼ phosphorus, PAD¼ peripheral artery disease,
rebrovascular disease.
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TABLE 2. Baseline Laboratory and Peritoneal Dialysis–Related Parameters
Variables
Total
(N¼ 81)
Faster RRF Decline
Group (N¼ 41)
Slower RRF Decline
Group (N¼ 40) P
Hemoglobin, g/dL 10.80 1.68 11.02 1.69 10.58 1.66 0.310
Ca, mg/dL 9.06 0.57 8.98 0.47 9.14 0.66 0.284
P, mg/dL 4.35 0.97 4.40 0.96 4.31 0.99 0.730
Uric acid, mg/dL 6.89 1.59 6.84 1.78 6.94 1.40 0.812
Glucose, mg/dL 109.3 45.4 117.2 56.9 101.1 28.1 0.167
HbA1c, % 6.22 1.20 6.60 1.36 5.90 0.97 0.044
ALP, IU/L 67.9 22.8 66.5 21.5 69.4 24.4 0.626
Protein, g/dL 6.16 0.71 6.22 0.77 6.10 0.66 0.518
Albumin, g/dL 3.40 0.51 3.45 0.59 3.36 0.43 0.507
BUN, mg/dL 49.0 14.5 48.1 14.7 50.0 14.6 0.611
Creatinine, mg/dL 6.84 2.30 6.58 2.02 7.10 2.57 0.378
GFR, mL/min/1.73m2 9.47 6.54 9.44 3.94 9.50 8.51 0.974
Sodium, mmol/L 139.1 3.3 138.9 3.7 139.2 3.0 0.730
Potassium, mmol/L 4.00 0.63 3.92 0.65 4.08 0.61 0.344
Chloride, mmol/L 99.5 3.9 99.3 4.0 99.8 3.8 0.569
Bicarbonate, mmol/L 27.2 3.2 27.4 3.5 27.0 2.8 0.640
Intact PTH, pg/mL 164.9 (74.3–290.3) 209.4 (121.9–323.2) 117.8 (43.5–245.3) 0.049
B2MG, mg/L 21.8 8.1 24.6 9.0 19.8 7.0 0.157
Cholesterol, mg/dL 177.9 45.8 179.5 48.2 176.3 43.9 0.788
Triglyceride, mg/dL 131.6 68.3 117.6 52.8 146.6 80.0 0.101
LDL-cholesterol, mg/dL 101.0 39.8 106.2 41.9 95.5 37.4 0.306
HDL-cholesterol, mg/dL 48.1 15.1 47.6 14.4 48.7 16.2 0.769
hs-CRP, mg/dL 4.49 (0.70–19.60) 9.57 (0.93–24.58) 1.37 (0.60–12.07) 0.057
Troponin T, ng/mL 0.034 (0.014–0.115) 0.054 (0.014–0.107) 0.031 (0.013–0.134) 0.741
NT-proBNP, pg/mL 5,278.0 (2,713.0–35,000.0) 11,211.0 (3,004.8–35,000.0) 5,278.0 (1,138.0–35,000.0) 0.740
Serum iron, mg/dL 73.8 40.9 71.6 45.4 76.0 36.4 0.677
TIBC, mg/dL 230.0 47.8 239.3 47.8 220.4 46.6 0.123
TSAT, % 32.3 17.2 30.1 18.7 34.6 15.4 0.316
Ferritin, ng/mL 147.2 (68.9–264.5) 90.7 (54.4–191.6) 211.8 (91.6–374.8) 0.017
Peritoneal dialysis–related parameters
APD 6 (7.4%) 4 (9.8%) 2 (5.0%) 0.675
Biocompatible solution 6 (7.4%) 4 (9.8%) 2 (5.0%) 0.675
Dialysate volume, mL/d 7,452.8 1,444.2 7,561.9 1,393.8 7,340.0 1,509.8 0.553
Urine volume, mL/d 1,121.2 968.4 1,176.8 1,149.3 1,063.7 753.1 0.652
Total weekly Kt/V urea 2.41 0.62 2.40 0.53 2.43 0.71 0.852
Peritoneal Kt/V urea 1.50 0.43 1.52 0.44 1.48 0.42 0.725
Renal Kt/V urea 0.91 0.66 0.88 0.44 0.95 0.83 0.687
Total weekly CCr, L/wk/1.73m2 108.2 36.9 112.6 30.6 103.4 42.6 0.335
Peritoneal CCr, L/wk/1.73m2 41.7 10.2 42.9 12.6 40.5 7.0 0.364
Renal CCr, L/wk/1.73m2 66.4 37.3 69.7 29.5 62.8 44.5 0.479
RRF, mL/min/1.73m2 4.68 2.88 4.83 2.15 4.52 3.53 0.680
RRF slope, mL/min/y/1.73m2 1.91 3.40 4.29 2.86 0.54 1.79 <0.001
LBM-Cr, kg 40.1 10.1 40.3 10.9 39.9 9.3 0.872
Lean body mass, % 64.8 12.5 65.8 13.8 63.9 11.1 0.561
nPNA, g/kg/d 0.99 0.21 0.97 0.21 1.01 0.22 0.432
D/P creatinine, 4 h 0.6959 0.1027 0.6957 0.1002 0.6962 0.1069 0.984
Groups of peritoneal equilibration test 0.765
High 12 (14.8%) 5 (12.2%) 7 (17.5%)
High average 44 (54.3%) 23 (56.1%) 21 (52.5%)
Low average 24 (29.6%) 13 (31.7%) 11 (27.5%)
Low 1 (1.2%) 0 (0.0%) 1 (2.5%)
ALP¼ alkaline phosphatase, APD¼ automated peritoneal dialysis, B2MG¼b2 microglobulin, BUN¼ blood urea nitrogen, Ca¼ calcium,
CCr¼ creatinine clearance, D/P¼ dialysate/plasma, GFR¼ glomerular filtration rate, HbA1c¼ hemoglobin A1c, HDL¼ high-density lipoprotein,
hs-CRP¼ high-sensitivity C-reactive protein, LBM-Cr¼ lean body mass estimated by creatinine kinetics, LDL¼ low-density lipoprotein, nPNA¼ -
protein equivalent of total nitrogen appearance, NT-proBNP¼N-terminal pro–B-type natriuretic peptide, P¼ phosphorus; PTH¼ parathyroid
hormone, RRF¼ residual renal function, TIBC¼ total iron-binding capacity, TSAT¼ transferrin saturation.
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TABLE 3. Baseline Values and 1-y Changes in Echocardiographic Parameters
Variables
Total
(N¼ 81)
Faster RRF Decline
Group (N¼ 41)
Slower RRF Decline
Group (N¼ 40) P
Baseline echocardiographic parameters
LVEDD, mm 50.9 5.3 50.7 4.8 51.1 5.8 0.756
LVESD, mm 34.5 5.7 34.2 5.1 34.8 6.4 0.665
LVEDVI, mL/m2 74.9 16.7 75.7 16.6 73.7 16.0 0.640
LVESVI, mL/m2 32.1 16.2 33.2 19.4 31.0 12.5 0.608
LAD, mm 39.4 7.0 38.9 7.2 40.0 6.9 0.570
LAVI, mL/m2 32.1 13.7 30.2 12.5 33.9 14.9 0.297
Fractional shortening, % 32.5 6.5 32.7 6.5 32.3 6.5 0.791
EF, % 62.3 11.1 62.7 10.9 61.8 11.4 0.777
Inter-ventricular thickness (diastolic phase), mm 11.2 2.0 11.0 2.0 11.3 2.0 0.654
Inter-ventricular thickness (systolic phase), mm 14.1 2.7 13.6 2.4 14.6 2.9 0.155
Posterior wall thickness (diastolic phase), mm 10.9 1.9 10.9 1.9 10.9 1.9 0.898
Posterior wall thickness (systolic phase), mm 14.7 2.4 14.5 2.4 15.0 2.4 0.351
LVMI, g/m2 131.0 37.1 130.2 37.1 131.8 37.8 0.869
Relative wall thickness 0.435 0.079 0.434 0.083 0.437 0.077 0.893
Geometry of left ventricle 0.941
Normal 17 (21.3%) 9 (22.7%) 8 (19.9%)
Concentric hypertrophy 31 (37.7%) 15 (35.6%) 16 (39.8%)
Eccentric hypertrophy 25 (31.1%) 12 (29.1%) 13 (33.2%)
Concentric remodeling 8 (9.8%) 5 (13.0%) 3 (6.6%)
E, m/s 0.686 0.219 0.702 0.248 0.670 0.190 0.584
A, m/s 0.788 0.210 0.795 0.236 0.780 0.182 0.792
E0, m/s 0.052 0.021 0.054 0.019 0.051 0.022 0.503
A0, m/s 0.077 0.018 0.079 0.019 0.075 0.017 0.407
S0, m/s 0.067 0.015 0.067 0.014 0.066 0.016 0.774
E/A ratio 0.89 0.33 0.91 0.37 0.87 0.29 0.619
E/E0 ratio 14.4 5.5 14.4 6.4 14.5 4.6 0.921
Diastolic dysfunction 0.594
Normal 11 (13.6%) 4 (9.8%) 7 (17.5%)
Relaxation abnormality 57 (70.4%) 30 (73.2%) 27 (67.5%)
Pseudonormalization 13 (16.0%) 6 (14.6%) 7 (17.5%)
DT, ms 216.9 63.0 214.6 63.2 219.1 63.7 0.787
RVSP, mm Hg 29.0 8.4 29.1 8.0 28.9 8.9 0.942
LAVI, >32mL/m2 35 (43.2%) 16 (39.0%) 19 (47.5%) 0.441
EF, <60% 28 (34.6%) 15 (36.6%) 13 (32.5%) 0.699
LVH 56 (69.1%) 27 (65.9%) 29 (72.5%) 0.517
E/E0 (>15) 33 (40.7%) 18 (43.9%) 15 (37.5%) 0.558
1-y changes in echocardiographic parameters
LVEDD slope, mm/y 1.21 7.23 1.00 7.89 3.48 5.76 0.016
LVESD slope, mm/y 1.01 7.26 0.92 8.18 3.00 5.63 0.037
LVEDVI slope, mL/m2/y 4.61 25.63 3.77 27.68 13.28 20.34 0.009
LVESVI slope, mL/m2/y 1.63 19.67 3.80 23.43 7.26 12.97 0.029
LAD slope, mm/y 0.19 7.08 1.03 6.73 1.46 7.33 0.179
LAVI slope, mL/m2/y 2.05 14.55 1.75 11.70 5.98 16.28 0.037
FS slope, %/y 0.44 9.04 0.13 10.87 1.02 6.81 0.631
EF slope, %/y 0.78 13.77 0.23 16.29 1.83 10.77 0.571
LVMI slope, g/m2/y 14.50 35.75 2.58 29.72 26.83 37.72 0.008
E/A slope, y1 0.006 0.594 0.079 0.753 0.098 0.346 0.279
E/E0 slope, y1 2.28 7.05 1.61 8.64 2.97 4.96 0.454
DT slope, ms/y 0.46 61.97 0.60 66.43 0.32 58.71 0.987
RVSP slope, mm Hg/y 4.25 14.04 2.72 15.22 5.78 12.92 0.467
DT¼ deceleration time, EF¼ ejection fraction, FS¼ fractional shortening, LAD¼ left atrial dimension, LAVI¼ left atrial volume index,
LVEDD¼ left ventricular end-diastolic dimension, LVEDVI¼ left ventricular end-diastolic volume index, LVESD¼ left ventricular end-systolic
dimension, LVESVI¼ left ventricular end-systolic volume index, LVH¼ left ventricular hypertrophy, LVMI¼ left ventricular mass index,
RRF¼ residual renal function, RVSP¼ right ventricular systolic pressure.
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using Student t test or Mann–Whitney U test for continuous
variables and the x2 test for categorical variables. Time-depen-
dent serial changes in echocardiographic parameters (LV end-
diastolic volume index [LVEDVI], LAVI, and LVMI) during the
first year of PD were compared between the 2 groups using the
linear mixed model (LMM), which utilized patient groups, time,
and interaction term between patient groups and time as fixed
effects. The final adjusted model was chosen on the basis of the
Akaike information criterion. In our implementation of the
mixed model, subject and intercept were treated as random
effects. To determine independent factors associated with the
rate of RRF decline, multivariate linear regression analysis was
performed. Cumulative survival curves for clinical outcomes
were created by the Kaplan–Meier method, and between-group
survival was compared by a log-rank test. The independent
prognostic power of RRF decline rate for CV composite out-
come, technique failure, or PD peritonitis was ascertained by
multivariate Cox proportional hazards regression analysis,
which included only the variables with P value <0.10 on the
univariate analysis. P values less than 0.05 were considered
statistically significant.
RESULTS
Baseline Characteristics
Koo et alThe baseline demographic and clinical characteristics are
shown in Table 1. The mean age was 51.5 11.8 years, and
49.4% of patients were males. The most common cause of
TABLE 4. Determining Factors for the Changes in Echocardiograph
Peritoneal Dialysis (Multivariate Linear Regression Analysis)
Slope of LVEDVI
HbA1c, %
Alkaline phosphatase, IU/L
Iron supplements
Biocompatible solution
Faster RRF decline group (vs slower RRF decline group)
Baseline echocardiographic parameters
LVEDVI, mL/m2
Slope of LAVI
Arrhythmia
Sodium, mmol/L
Plavix
Faster RRF decline group (vs slower RRF decline group)
Baseline echocardiographic parameters
LAVI, mL/m2
Ejection fraction, %
E/A
Slope of LVMI
Congestive heart failure
Alkaline phosphatase, IU/L
Albumin, g/dL
APD (vs CAPD)
Faster RRF decline group (vs slower RRF decline group)
Baseline echocardiographic parameters
LVMI, g/m2
APD¼ automated peritoneal dialysis, CAPD¼ continuous ambulatory pe
index, LVEDVI¼ left ventricular end-diastolic volume index, LVMI¼ left
6 | www.md-journal.comESRD was diabetes mellitus (DM, 38.3%), followed by glo-
merulonephritis (24.7%) and hypertension (14.8%). When
patients were dichotomized into 2 groups according to the
median value of RRF slope (1.60mL/min/y/1.73m2), systolic
blood pressure, pulse pressure (PP), and the proportion of
patients on diuretics were significantly higher in the ‘‘faster’’
RRF decline group compared with those in the ‘‘slower’’ RRF
decline group.
Among laboratory variables, HbA1c and iPTH levels were
significantly higher in the ‘‘faster’’ RRF decline group com-
pared with those in the ‘‘slower’’ RRF decline group, while
serum ferritin levels were significantly lower. There was a trend
of higher hs-CRP levels in patients with rapid RRF decline
compared with those in the ‘‘slower’’ RRF decline group, but it
did not reach statistical significance (Table 2).
On the other hand, PD-related parameters such as the
proportion of patients on automated PD or with biocompatible
nonglucose PD solution use, weekly Kt/V urea and creatinine
clearance, baseline RRF, and the distribution of peritoneal
characteristics were not significantly different between the 2
groups (Table 2). Baseline echocardiographic parameters were
also comparable between the 2 groups (Table 3).
One-Year Serial Changes in Echocardiographic
Parameters According to the Rate of RRF Decline
Medicine  Volume 94, Number 7, February 2015On a simple comparison using Student t test, there were
significant decreases in LVEDVI, LV end-systolic volume
index (LVESVI), LAVI, and LVMI during the first year of
ic Parameters, LVEDVI, LAVI, and LVMI, During the First Year of
Regression Coefficient P
5.056 0.098
0.128 0.469
12.971 0.198
25.349 0.051
17.953 0.019
0.452 0.035
11.056 0.107
0.794 0.047
8.794 0.046
8.543 0.006
0.468 0.005
0.162 0.283
8.465 0.081
25.960 0.006
0.401 0.018
3.417 0.540
7.367 0.621
21.004 0.005
0.416 <0.001
ritoneal dialysis, HbA1c¼ hemoglobin A1c, LAVI¼ left atrial volume
ventricular mass index, RRF¼ residual renal function.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
PD in patients with ‘‘slower’’ RRF decline compared with those
in the ‘‘faster’’ RRF decline group (Table 3). In addition, the
rate of RRF decline was a significant independent factor
associated with changes in LVEDVI, LAVI, and LVMI on
multivariate linear regression analysis (Table 4). Next, we
compared the time-dependent 1-year serial changes in echo-
cardiographic parameters between the ‘‘faster’’ and ‘‘slower’’
RRF decline groups (Table 5; Figure 1; Supplementary Figure
1, http://links.lww.com/MD/A167). LVEDVI and LVMI values
were comparable between the 2 groups at baseline and
decreased similarly until 6 months. After 6 months, however,
patients with ‘‘slower’’ RRF decline showed a continuous
regression pattern, while these values stopped decreasing in
the ‘‘faster’’ RRF decline group, resulting in significant differ-
ences between the 2 groups at 12 months (P¼ 0.045 and 0.003,
respectively). LMM further confirmed that the overall reduction
rates of LVEDVI and LVMI were significantly greater in
patients with ‘‘slower’’ RRF decline compared with those in
Medicine  Volume 94, Number 7, February 2015the ‘‘faster’’ RRF decline group, even after adjusting for
confounding factors (P¼ 0.047 and 0.001, respectively). LAVI
also decreased gradually in the ‘‘slower’’ RRF decline group,
TABLE 5. Time-Dependent Changes in Echocardiographic Param
Decline
Faster RRF Decline
Group (N¼ 41)
LVEDVI, mL/m2
Baseline 75.7 16.6
6-mo 69.9 13.0
12-mo 77.8 30.1
LVEDVI slope, mL/m2/y 3.77 27.68
LMM 1
LMM 2

LMM 3y
LAVI, mL/m2
Baseline 30.2 12.5
6-mo 30.5 12.3
12-mo 33.2 16.8
LAVI slope, mL/m2/y 1.75 11.70
LMM 1
LMM 2z
LMM 3§
LVMI, g/m2
Baseline 130.2 37.1
6-mo 121.0 41.1
12-mo 129.9 36.0
LVMI slope, g/m2/y 2.58 29.72
LMM 1
LMM 2jj
LMM 3
CI¼ confidence interval, LAVI¼ left atrial volume index, LMM¼ linea
LVMI¼ left ventricular mass index, PD¼ peritoneal dialysis, RRF¼ residu
Adjusted for left ventricular end-diastolic volume index.
yAdjusted for the usage of iron supplements and biocompatible dialys
ventricular end-diastolic volume index.
zAdjusted for the usage of Plavix, serum sodium levels, and LAVI.
§ Adjusted for arrhythmia, usage of Plavix, serum sodium levels, LAVI,
jjAdjusted for congestive heart failure, serum alkaline phosphatase level
Adjusted for congestive heart failure, automated peritoneal dialysis, se
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.while it was slightly increased at 6 and 12 months in the
‘‘faster’’ RRF decline group, resulting in a significant differ-
ence in LMM (P¼ 0.048).
In contrast, the changes in echocardiographic parameters
during the first year of PD showed no differences between
patients who were grouped by median values of baseline RRF
(Supplementary Table 1, http://links.lww.com/MD/A168).
Independent Factors Associated With the Rate of
RRF Decline
On multivariate linear regression analysis, natural log
values of hs-CRP (Ln hs-CRP) and baseline E/A values were
significant independent factors associated with the rate of RRF
decline during the first year of PD. After including the 1-year
changes in echocardiographic parameters (LVEDVI, LAVI, or
LVMI) into the successive models, PP, Ln hs-CRP levels,
baseline E/A, and the slope of each echocardiographic
parameter were found to be significant determinants of the
RRF Decline Rate and Changes in EchocardiographyRRF decline rate. Among 3 variances in cardiac performance,
only the changes in LAVI remained statistically significant in
the final model (Table 6).
eters During the First Year of PD, According to the Rate of RRF
Slower RRF Decline
Group (N¼ 40) P (95% CI)
73.7 16.0 0.640 (10.503, 6.507)
67.9 16.9 0.759 (15.391, 11.388)
64.5 14.4 0.045 (26.175, 0.337)
13.28 20.34 0.009 (29.748, 4.347)
0.027 (11.664, 0.713)
0.046 (10.292, 0.085)
0.047 (12.061, 0.106)
33.9 14.9 0.297 (3.331, 10.707)
31.5 17.6 0.873 (12.101, 14.140)
27.7 10.7 0.176 (13.494, 2.532)
5.98 16.28 0.037 (14.971, 0.483)
0.045 (6.048, 0.065)
0.042 (6.330, 0.126)
0.048 (5.596, 0.014)
131.8 37.8 0.869 (17.576, 20.757)
123.7 39.6 0.866 (30.614, 36.120)
100.6 29.4 0.003 (47.831, 10.812)
26.83 37.72 0.008 (41.915, 6.572)
0.002 (19.328, 4.750)
0.001 (17.790, 5.051)
0.001 (17.756, 5.048)
r mixed model, LVEDVI¼ left ventricular end-diastolic volume index,
al renal function.
ate, serum hemoglobin A1c and alkaline phosphatase levels, and left
ejection fraction, and E/A.
s, and LVMI.
rum alkaline phosphatase and albumin levels, and LVMI.
www.md-journal.com | 7
90
80
70
60
50
40
36
32
28
24
20
150
140
130
120
110
100
90
80
Slower RRF decline group
Faster RRF decline group
0 mo 6 mo 12 mo
0 mo 6 mo 12 mo
0 mo 6 mo 12 mo
LV
ED
VI
, m
L/
m
2
LA
VI
, m
L/
m
2
LV
M
I, 
g/
m
2
A
B
C
FIGURE 1. Time-dependent serial changes in echocardiographic
parameters according to the rate of RRF decline. During the first
year of PD, LVEDVI (A), LAVI (B), and LVMI (C) decreased con-
tinuously in patients with ‘‘slower’’ RRF decline, while no improve-
ment or a slightly deteriorating pattern was observed in the
‘‘faster’’ RRF decline group. LAVI¼ left atrial volume index, LVED-
VI¼ left ventricular end-diastolic volume index, LVMI¼ left ven-
tricular mass index, PD¼peritoneal dialysis, RRF¼ residual renal
Koo et alClinical Outcomes According to the Rate of RRF
Decline
During a mean follow-up duration of 31.9 months, 4
(4.9%) patients died. The event rates for all-cause mortality,
composite of death or hospitalization, infection composite, and
new-onset CV disease were not different between the 2 groups.
In contrast, compared with patients with ‘‘slower’’ RRF
decline, the ‘‘faster’’ RRF decline group showed a significantly
higher rate of technique failure (18.80 vs 4.19 events/100
patient-years [PY], P¼ 0.006). CV composite (20.29 vs 7.18
events/100 PY, P¼ 0.098) and PD peritonitis (15.73 vs 4.95
events/100 PY, P¼ 0.064) also developed more frequently in
the ‘‘faster’’ RRF decline group, but the differences did not
function.reach statistical significance (Table 7). However, Kaplan–
Meier analysis revealed that CV composite, technical failure,
and PD peritonitis event-free survivals were significantly higher
8 | www.md-journal.comin the ‘‘slower’’ RRF decline group compared with those in the
‘‘faster’’ RRF decline group (Figure 2).
Multivariate Cox regression analysis demonstrated that
patients with rapid RRF decline had 4.82-, 4.44-, and 7.37-fold
higher risks for CV composite outcome (P¼ 0.032), technique
failure (P¼ 0.031), and PD peritonitis (P¼ 0.017), respect-
ively. Moreover, the significance of the rate of RRF decline
was more powerful than that of baseline RRF values in pre-
dicting each clinical outcome (Table 8). However, the signifi-
cant impact of RRF decline rate on CV composite and technique
failure was no longer observed when further adjustments were
made with 1-year changes in echocardiographic parameters
(Supplementary Table 2, http://links.lww.com/MD/A169).
DISCUSSION
A number of previous studies have shown that lower RRF
is associated with increased morbidity and mortality in ESRD
patients on HD or PD.11–17,27 Furthermore, RRF and cardiac
function are known to influence each other.28 Therefore, some
changes in echocardiographic findings are expected over time
as RRF declines in incident dialysis patients, but this trend has
not previously been explored. In the current study, we demon-
strate for the first time that slow RRF decline is significantly
associated with time-dependent decreases in LVEDVI, LAVI,
and LVMI during the first year of PD, indicating an improve-
ment in cardiac morphology and function. Furthermore, a rapid
decline in RRF independently predicted adverse clinical out-
comes such as CV composite, technique failure, and
PD peritonitis.
RRF plays a pivotal role in maintaining sodium and water
balance of dialysis patients, and thus loss of RRF leads to
chronic volume expansion and hypertension.9,10 The severity of
anemia is also known to correlate with RRF.29,30 All these
factors contribute to the development of LVH and left atrial
enlargement (LAE). Therefore, it is a matter of course that LVH
and LAE progress as RRF declines, but this trend has not
previously been explored in dialysis patients. As expected,
the present study found that there were increases in LVEDVI,
LVESVI, and LAVI in patients with rapid RRF decline. How-
ever, these parameters were relatively decreased in the
‘‘slower’’ RRF decline group, which seemed to be partly
attributed to an increase in mean RRF in this group. In contrast,
LVMI was decreased in both groups even though the reduction
of LVMI was significantly greater in patients with ‘‘slower’’
RRF decline. We inferred that correction of uremia and hyper-
parathyroidism rather than improvement in fluid balance and/or
anemia contributed to the regression of LVMI in the ‘‘faster’’
RRF decline group in spite of a significant decrease in RRF.
Mounting evidence indicates that LVH is a powerful
independent predictor of CV mortality in patients with chronic
kidney disease and ESRD.4,5 The change in LVH has also been
considered a strong prognostic factor in these patients. A
previous prospective study on prevalent HD patients revealed
that the rates of LVMI increase were significantly higher in
patients with incident CV events than in those without such
events, and that CV event-free survival in patients with changes
in LVMI below the 25th percentile was significantly higher than
in those with changes above the 75th percentile.2 Similarly, in a
cohort study of 153 incident ESRD patients receiving HD, a
10% reduction in LV mass during a mean follow-up duration of
Medicine  Volume 94, Number 7, February 201554 months resulted in a 22% decrease in all-cause mortality and
a 28% decrease in CV mortality. Furthermore, in that study, LV
mass regression was independently associated with improved
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 6. Determining Factors for the Slope of Residual Renal Function
Variables
Model 1 Model 2 Model 3 Model 4 Model 5
Regression
Coefficient
P Regression
Coefficient
P Regression
Coefficient
P Regression
Coefficient
P Regression
Coefficient P
Sex (female) 1.175 0.127 1.023 0.175 1.136 0.107 0.955 0.196 1.025 0.154
Pulse pressure, mm Hg 0.034 0.060 0.034 0.048 0.035 0.032 0.037 0.028 0.038 0.023
Ln hs-CRP, mg/dL 0.509 0.012 0.414 0.036 0.597 0.002 0.426 0.027 0.528 0.008
Baseline echocardiographic parameters
E/A 3.285 0.006 3.798 0.001 4.480 <0.001 3.346 0.003 4.171 0.001
1-y changes in echocardiographic parameters
LVEDVI slope, mL/m2/y — — 0.031 0.031 — — — — 0.008 0.697
LAVI slope, mL/m2/y — — — — 0.080 0.002 — — 0.063 0.039
LVMI slope, g/m2/y — — — — — — 0.026 0.010 0.020 0.139
Model 1: adjusted for demographics (sex and pulse pressure), laboratory findings (Ln hs-CRP), and baseline echocardiographic parameters (E/A).
Model 2: Model 1þLVEDVI slope. Model 3: Model 1þLAVI slope. Model 4: Model 1þLVMI slope. Model 5: Model 1þ slope of LVEDVI,
sfor
Medicine  Volume 94, Number 7, February 2015 RRF Decline Rate and Changes in Echocardiographypatient survival even after adjustment for age, gender, DM,
history of CV disease, and all nonspecific CV risk factors.3 On
the other hand, since considerable recent evidence has shown
that LAV is a significant risk factor for poor outcome in patients
with various CV diseases, such as cardiomyopathy, acute
myocardial infarction, and preexisting atrial fibrillation,31–34
several studies have been conducted and demonstrated that
LAV predicts mortality in the HD population on long-term
low-salt diets and in ESRD patients with LVH.6,35 In addition,
Tripepi et al8 found that LAV indexed for height but not crude
or BSA-adjusted LAV was independently associated with
mortality in ESRD patients on dialysis. Moreover, they showed
that changes in LAV predicted incident fatal and nonfatal CV
events in dialysis patients, independent of baseline LAV or LV
mass.36 Exclusively in PD patients, Kim et al7 also demon-
strated that LAVI was an independent predictor of all-cause and
CV mortality, and that increased LAVI better predicted adverse
outcomes than other echocardiographic parameters. Based on
LAVI, and LVMI. LAVI¼ left atrial volume index, Ln hs-CRP¼ log tran
diastolic volume index, LVMI¼ left ventricular mass index.these findings, baseline LVH and/or LAV as well as changes in
these parameters seem to be important prognostic factors for
clinical outcomes in ESRD patients on dialysis.
TABLE 7. Comparisons of Clinical Outcomes According to the R
Faster RRF Decline Group
(N¼ 41)
N (%) Rates (/100 PY
All-cause mortality 3 (7.3) 3.54
Composite

34 (82.9) 79.82
CV composite

15 (36.6) 20.29
Infection composite

18 (43.9) 28.46
New-onset CV disease 15 (36.6) 20.29
Technique failure 16 (39.0) 18.80
PD peritonitis 12 (29.3) 15.73
CV¼ cardiovascular, PD¼ peritoneal dialysis, PY¼ patient-year, RRF¼
Composite: composite of death or hospitalization.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Since the first study by Maiorca et al,11 which demon-
strated that RRF was significantly higher in patients who
survived compared with that in those who died (2.73 2.49
vs 0.33 0.86mL/min, P¼ 0.0005), and that RRF was an
independent predictor of survival in 102 prevalent dialysis
patients, many subsequent studies have shown a significant
impact of RRF on the clinical outcomes in ESRD patients on
HD or PD. The Netherlands Cooperative Study on the Ade-
quacy of Dialysis-2 demonstrated that there was a 56% decrease
in relative risk of death (P< 0.0001) with an increase of 1/week
in renal Kt/V urea in 740 incident HD patients. In that study, the
influence of dialysis dose on mortality was found to be sig-
nificant only in anuric patients.37 Termorshuizen et al14 also
showed that a 12% reduction in mortality rate (P¼ 0.039) was
observed for each mL/min/1.73m2 increase in RRF in 413
incident PD patients, and that there was no significant effect
of peritoneal creatinine clearance on patient survival, which was
consistent with the results of previous studies by Szeto et al15
med high-sensitivity C-reactive protein, LVEDVI¼ left ventricular end-and Rocco et al.16 In contrast to numerous investigations on the
association of baseline RRF and clinical outcome in ESRD
patients, the impact of the RRF decline rate on clinical outcome
ate of RRF Decline
Slower RRF Decline Group
(N¼ 40)
P) N (%) Rates (/100 PY)
1 (2.5) 1.56 0.616
31 (77.5) 56.75 0.540
8 (20.0) 7.18 0.098
14 (35.0) 16.52 0.413
12 (30.0) 12.31 0.530
5 (12.5) 4.19 0.006
5 (12.5) 4.95 0.064
residual renal function.
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Koo et al Medicine  Volume 94, Number 7, February 2015has been rarely explored in this population. A previous study
FIGURE 2. Kaplan–Meier curves for CV composite outcome (A), te
decline rate (1.60 mL/min/y/1.73 m2) showed significantly wor
CV¼ cardiovascular, PD¼peritoneal dialysis, RRF¼ residual renal ffrom the United Kingdom revealed that loss of RRF occurred
significantly earlier in nonsurvivors than in survivors (0.37 vs
0.68, P¼ 0.02 at 6 months, 0.19 vs 0.54, P¼ 0.01 at 12 months)
TABLE 8. Multivariate Cox Proportional Hazard Regression Analys
and PD Peritonitis
Variables
Cardiovascular composite outcome
Pulse pressure, mm Hg
Diabetes
Ln hs-CRP, mg/dL
Lean body mass, %
nPNA, g/kg/d
Baseline RRFmedian (vs >median)
Faster RRF decline group (vs slower RRF decline group)
Baseline echocardiographic parameters
EF 60% (vs >60%)
Technique failure
Albumin, g/dL
Cholesterol, mg/dL
Vitamin D
Baseline RRFmedian (vs >median)
Faster RRF decline group (vs slower RRF decline group)
Baseline echocardiographic parameters
Diastolic dysfunction
Relaxation abnormality versus normal
Pseudonormalization versus normal
PD peritonitis
Sex (female)
Charlson comorbidity index
Glucose, mg/dL
Sodium, mmol/L
Ln hs-CRP, mg/dL
Baseline RRFmedian (vs >median)
Faster RRF decline group (vs slower RRF decline group)
Baseline echocardiographic parameters
Left ventricular hypertrophy
CI¼ confidence interval, EF¼ ejection fraction, HR¼ hazard ratio, Ln h
protein equivalent of total nitrogen appearance, PD¼ peritoneal dialysis, R
10 | www.md-journal.comdespite comparable RRF values at the start of PD treatment.38
nique failure (B), and PD peritonitis (C). Patients with ‘‘faster’’ RRF
linical outcomes compared with the ‘‘slower’’ RRF decline group.
tion.Furthermore, Liao et al18 observed that patients with fast RRF
decline had worse survival and increased risk of technique
failure, and that the rate of RRF decline was an independent
is for Cardiovascular Composite Outcome, Technique Failure,
HR 95% CI P
1.021 0.983–1.062 0.277
5.290 1.165–24.016 0.031
1.309 0.513–1.136 0.184
0.980 0.924–1.039 0.491
0.823 0.066–10.197 0.879
3.777 1.013–14.082 0.048
4.815 1.147–20.218 0.032
3.207 0.948–10.845 0.061
0.529 0.177–1.577 0.253
0.991 0.976–1.006 0.245
0.279 0.054–1.428 0.125
1.896 0.455–7.904 0.380
4.439 1.147–17.179 0.031
4.344 0.347–54.398 0.255
20.125 1.118–236.288 0.042
10.079 1.421–71.472 0.021
1.303 0.876–1.938 0.191
1.018 0.998–1.038 0.081
0.858 0.699–1.054 0.144
1.144 0.592–1.776 0.566
8.507 1.279–56.604 0.027
7.368 1.427–38.041 0.017
19.407 1.477–255.046 0.024
s-CRP¼ log transformed high-sensitivity C-reactive protein, nPNA¼ -
RF¼ residual renal function.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
factor associated with patient and technique survival and was a
more powerful prognostic factor than basal RRF. However,
these 2 studies did not clearly elucidate the mechanism of
adverse clinical outcomes due to faster RRF decline. In this
study, we demonstrated that CV composite was significantly
worse in the ‘‘faster’’ RRF decline group compared with that in
the ‘‘slower’’ RRF decline group, which was consistent with the
results of aforementioned studies. In addition, there were
significant differences in the changes in LVEDVI, LVESVI,
LAVI, and LVMI between patients with ‘‘faster’’ and
‘‘slower’’ RRF decline, indicating deterioration or less
improvement of cardiac performance in the ‘‘faster’’ RRF
decline group. Moreover, the significant impact of the RRF
decline rate on CV composite was no longer observed when
further adjustments were made with 1-year changes in echo-
cardiographic parameters. These findings suggest that the influ-
ence of RRF decline on CV composite was in part attributed to
the changes in cardiac performance in incident PD patients.
On the other hand, technical survival and peritonitis event-
free survival were significantly higher in our patients with
‘‘slower’’ RRF decline. An observational study by Szeto
et al27 found that PD patients with RRF had significantly lower
peritonitis rates compared with dialysis-dependent PD patients
(1 episode per 44.4 vs 13.6 patient-months, P< 0.05). Perez
Fontan et al39 also showed that lower RRF at the start of PD was
an independent risk factor for at least 1 episode of peritonitis
and its related mortality in 565 PD patients. Furthermore, a
study by Han et al40 revealed that time to first peritonitis episode
was significantly longer and peritonitis rate was significantly
lower in patients with RRF> 5mL/min/1.73m2 compared with
in those with RRF 5mL/min/1.73m2 (0.24 vs 0.57 episode
per PY, P< 0.001). The exact underlying mechanisms by which
RRF impacts technical failure and peritonitis are not clear, but
Wang et al41 postulated that loss of RRF may compromise the
general condition and immunocompetence of PD patients. Since
peritonitis is the principal cause of technical failure in PD
patients,42 lower peritonitis rate may partly account for a
significantly higher technical survival rate in our ‘‘slower’’
RRF decline group.
Previous studies have demonstrated that high transporter,
DM, CHF, hypotension, extracellular fluid volume depletion,
use of diuretics, and peritonitis are associated with the loss of
RRF in PD patients,9 although controversy exists concerning
the role of diuretics in RRF.18,43 In the current study, the
proportions of DM patients and patients on diuretics were
higher in the ‘‘faster’’ RRF decline group, but DM and diuretics
usage were not independent predictors of RRF decline rates on
multivariate analysis. Instead, hs-CRP levels, baseline E/A, and
changes in LAVI were significant determinants of the rate of
RRF decline. Several previous studies have found that high
baseline LAVI is an independent risk factor for a rapid decline
in RRF in incident PD patients.44,45 It is true that chronic heart
failure can provoke renal hypoperfusion and increase renal
vascular resistance, which in turn results in the impairment
of renal function. In addition, atrial stretch facilitates neuro-
hormonal activation, including the production of vasoconstric-
tive mediators, leading to further aggravation of renal
dysfunction.28 In diastolic dysfunction, moreover, mild volume
changes in cardiac filling may induce a significant decrease in
cardiac output and systemic hypotension, resulting in reduced
renal perfusion.46 Since left atrial size is regarded as a more
Medicine  Volume 94, Number 7, February 2015stable indicator of the duration and severity of diastolic dys-
function than any other echocardiographic parameter,47 it is
surmised that LV diastolic dysfunction and LAE can influence
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.the decline in RRF. hs-CRP level, an indicator of inflammation,
has been shown to be significantly associated with cardiac
dysfunction, which may contribute to a more rapid decline in
RRF.48 Furthermore, systemic inflammation-induced cytokines
may have a direct deleterious effect on renal perfusion.49
Several shortcomings of the present study should be dis-
cussed. First, since this was a retrospective medical record–
based study, the observational nature could limit the causational
interpretation of our study results. We cannot determine con-
clusively if RRF decline influenced the changes in echocardio-
graphic parameters, or vice versa. However, multivariate
analysis revealed that the RRF decline rate was a significant
independent factor associated with changes in LVEDVI, LAVI,
and LVMI, and that the changes in these echocardiographic
parameters were significant independent predictors of the rate
of RRF decline, suggesting an interrelationship between RRF
and cardiac performance. Second, only a small number of
Korean incident PD patients from a single center were included.
Therefore, the association between the rate of decline in RRF
and the changes in echocardiographic parameters may not be
generalizable to other populations. Third, the mortality and
event rates were relatively low compared with those of previous
studies onWestern ESRD patients, but they were comparable to
those of Japanese ESRD patients.50 A small number of patients
and events and a relatively short follow-up duration may limit
the power of the statistical analysis in this study. Fourth, we
excluded patients who did not receive follow-up echocardio-
graphy more than once during the first year of PD, and thus
selection bias may have existed. Lastly, the current study
focused on the 1-year changes in RRF and echocardiographic
parameters; therefore, the results might be different with an
extended study period of 2 or 3 years.
Despite these limitations, we believe that the present study
is a meaningful investigation demonstrating for the first time
that cardiac performance is significantly worsened or less
improved in incident PD patients with rapid RRF decline. In
addition, rapid RRF decline rate is found to be a significant
independent predictor of adverse clinical outcomes including
CV composite, technique failure, and PD peritonitis. Based on
these findings, preservation of RRF is important for conserving
cardiac performance, resulting in an improvement in clinical
outcome in incident PD patients.
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